Stoke Therapeutics completes dosing in first two cohorts of Phase 1 OSPREY trial for STK-002 in optic atrophy

• Stoke Therapeutics flagged new Phase 1 progress for STK-002, an RNA-based therapy aimed at autosomal dominant optic atrophy.
• Preclinical findings and early clinical updates will be presented at the American Academy of Ophthalmology meeting on Oct. 9-12, 2026.
• Dosing has finished in the first two cohorts of the OSPREY study, with the third cohort expected to complete by year-end 2026.
• Initial safety and efficacy readouts are expected in H1 2027, a key marker for next-stage development decisions.
• The program targets the disease’s genetic driver by seeking to raise OPA1 protein levels, with the goal of improving vision.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610060800BIZWIRE_USPR_____20261001_BW196435) on October 06, 2026, and is solely responsible for the information contained therein.